Navigation Links
Gladstone and Izumi Bio in partnership in regenerative medicine and cardiovascular disease
Date:6/16/2008

SAN FRANCISCO, CA June 16, 2008 --- iZumi Bio, Inc. and The J. David Gladstone Institutes, an independent non-profit biomedical research organization, have announced a major research collaboration and licensing agreement to focus on applications for induced pluripotent stem (iPS) cells.

iPS cells are "reprogrammed" adult cells that have similar properties and potential to those of human embryonic stem (ES) cells, yet do not raise the same ethical concerns and can be generated in a patient-specific manner to avoid immune rejection.

"The Gladstone relationship with iZumi Bio combines our work in cardiovascular disease and stem cell science with first-class investors and an experienced management team," said Deepak Srivastava, MD Director of the Gladstone Institute of Cardiovascular Disease. "It's an ideal model for advancing science in a focused, efficient way."

"Gladstone is emerging as a global leader in regenerative medicine and its applications to heart disease," said Thane Kreiner, PhD, iZumi Bio Chief Executive Officer. "This collaboration underscores our commitment and ability to translate the best research in iPS technology to products that address important unmet medical needs."

Elements of the broad partnership include iZumi Bio taking a license to certain Gladstone patents and sponsoring research related to iPS cells and cardiovascular disease. Dr. Srivastava will lead the research and will join iZumi Bio's scientific advisory board.

"We're delighted to add this important new company to our translational research partners," said Gladstone President, Robert W. Mahley, MD, PhD, "We look forward to developing iPS technology into treatments and cures."


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Page: 1

Related biology news :

1. Gladstones Shinya Yamanaka wins prestigious Shaw Prize
2. Smart greenhouse research partnership unveiled
3. National Lung Cancer Partnership and LUNGevity Foundation
4. National Lung Cancer Partnership announces winner of 2007 Career Development Award
5. Springer expands publishing partnership with the Biomedical Engineering Society
6. Plant Physiology and TAIR partnership will provide genetic information to public database
7. KAUST announces academic excellence alliance partnership with Imperial College London
8. Cell Press announces new partnership with the Biophysical Society
9. Citizen Science -- a celebration of partnership between academia and local people
10. Oak Ridge to lead auto supplier R&D partnership
11. GM, Coskata partnership builds on Oklahoma State University biofuels research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: